



December 30, 2025

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (E), Mumbai- 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Intimation of Schedule of Analyst / Investor Call

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Company will hold its Q2 FY26 earnings conference call (i.e. post earnings/quarterly call) on Monday, January 05, 2026 at 12:00 p.m. (IST) to discuss the financial results of the Company for the second quarter and half year ended September 30, 2025 as per details enclosed herewith.

This intimation is also being made available on the website of the Company at www.coronaremedies.com

You are requested to take note of the above.

Thanking you.

Your faithfully,

For **CORONA Remedies Limited**

CHETNA PRABHAT
KUMAR
DHARAJIYA

Digitally signed by CHETNA
PRABHAT KUMAR DHARAJIYA
Date: 2025.12.30 19:05:34
+05'30'

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

JM Financial Institutional Securities invites you to the
2QFY26 earnings conference call with

CORONA Remedies Limited

on Monday, 5th January 2026

12:00 PM IST | 01:30 AM USA EDT | 06:30 AM UK TIME | 02:30 PM HK/SINGAPORE TIME

Company Participants

Mr. Nirav Mehta

Managing Director & CEO

Mr. Ankur Mehta

Joint Managing Director

Mr. Bhavin Bhagat

Chief Financial Officer

AND

Senior Management Team

Universal Dialin:

+91-22-6280 1366 / +91-22-7115 8267

Toll Free Number – International

USA:
1 866 746 2133

UK:
0 808 101 1573

Singapore:
800 101 2045

Hong Kong:
800 964 448

Please dial-in 10 minutes prior to the conference schedule to ensure that you are connected in time

[Diamond Pass Link:](#)



Click here to
ExpressJoin the Call

[For further information, please contact](#)

| | | |
|------------------|------------------|-----------------------|
| Mr. Amey Chalke | +91-22-6630 3056 | amey.chalke@jmfl.com |
| Mr. Abin Benny | +91-22-6970 3621 | abin.benny@jmfl.com |
| Mr. Gourav Bhama | +91-22-6970 3679 | gourav.bhama@jmfl.com |

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: ashley.johnson@jmfl.com

Grievance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks.

Read all the related documents carefully before investing.

Safe harbor:

The proposed management discussion and comments thereof may include forward-looking statements. Forward-looking statements are statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact. All forward looking statements are subject to risks, uncertainties and assumptions that could cause actual results of operations and financial conditions to differ materially from those contemplated by the relevant statement. All Conference Call Participants should not place undue reliance on these forward-looking statements. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities Limited or provide any assurance of returns to investors.